帮助 关于我们

返回检索结果

奥沙利铂联合卡培他滨治疗38例晚期胃癌的疗效
Oxaliplatin Plus Capecitabine for Advanved Gastric Cancer: Report of 38 Cases

查看参考文献12篇

管梅 1   张路 2   赵林 1   白春梅 1 *  
文摘 目的探讨奥沙利铂联合卡培他滨(XELOX)方案治疗晚期胃癌的疗效和安全性.方法回顾性分析2004年5月至2009年10月北京协和医院肿瘤内科收治的使用XELOX方案治疗晚期胃癌患者38例.化疗方案:奥沙利铂静滴2h,第1天给药;卡培他滨分2次口服,第1~14天给药;每3周重复.按实体瘤的疗效评价标准评价疗效,按美国国立癌症研究所的常见不良反应判定标准评价毒副反应.结果 3周期后评价疗效:一线化疗34例,二线化疗4例.一线化疗患者中32例可评估,完全缓解0例(0.0%),部分缓解8例(25.0%),疾病稳定14例(43.8%),疾病进展10例(31.2%).中位随访9.5个月(4~46个月),23例出现疾病进展,中位无进展生存时间为7.0个月(95%CI为4.5~9.5个月);20例已死亡(均为肿瘤相关死亡),中位总生存时间为12.0个月(95%CI为9.8~14.2个月);1年生存率40.6%,2年生存率23.7%.3~4度不良反应主要有粒细胞减少(10.5%),血小板减少(2.6%),恶心(7.9%),呕吐(5.3%).结论 XELOX作为一线化疗方案治疗晚期胃癌有效,安全
其他语种文摘 Objective To evaluate the efficacy and toxicity of the combination chemotherapy of oxali-platin with capecitabine(XELOX)in patients with advanced gastric cancer. Methods Thirty-eight advanced gastric cancer patients who received XELOX regimen during 2004-2009 were analyzed retrospectively. The combination chemotherapy included oxaliplatin as 2-hour infusion on day 1 and capecitabine po bid on days 1 to 14. Treatment was repeated every 3 weeks. Results XELOX regime was applied as first-line therapy in 34 pa-tients and as second-line therapy in 4 patients. After three cycles of chemotherapy, the outcomes in 32 patients who received XELOX as the first-line therapy included partial response(n = 8,25.0%), stable disease(n = 14,43.8%), and progressive disease(n = 10,31.2%);no patient achieved complete response. The median time to progression and overall survival time were 7.0 months(95% CI:4.5-9.5 months)and 12 months(95% CI:9.8-14.2 months), respectively. One-year and two-year survival rates were 40.6% and 23.7%, respectively. Grade 3-4 toxicities including neutropenia(10.5%), thrombocytopenia(2.6%), nausea(7.9%), and vomitting(5.3%)were noted in a few patients. Conclusion XELOX regimen can be effectively and safely applied as first-line treatment for advanced gastric cancer patients
来源 中国医学科学院学报 ,2010,32(4):407-411 【核心库】
DOI 10.3881/j.issn.1000-503x.2010.04.010
关键词 晚期胃癌 ; 奥沙利铂 ; 卡培他滨
地址

1. 中国医学科学院北京协和医学院北京协和医院肿瘤内科, 北京, 100730  

2. 中国医学科学院北京协和医学院北京协和医院物理康复科, 北京, 100730

语种 中文
文献类型 研究性论文
ISSN 1000-503X
学科 肿瘤学
文献收藏号 CSCD:4031450

参考文献 共 12 共1页

1.  孙秀娣. 中国胃癌死亡率20年变化情况分析及其发展趋势预测. 中华肿瘤杂志,2004,26(1):4-9 CSCD被引 131 次    
2.  Hundahl SA. The National Cancer Data Base report on poor survival of US gastric carcinoma patients treated with gastrectomy. Cancer,2000,88(4):921-932 CSCD被引 21 次    
3.  Murad AM. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer,1993,72(1):37-41 CSCD被引 16 次    
4.  Pyrhonen S. Randomised comparison of fluorou-racil, epidoxorubicin and methotrexate (FEMTX)plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer,1995,71(3):587-591 CSCD被引 18 次    
5.  Glimelius B. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol,1997,8(2):163-168 CSCD被引 26 次    
6.  Kang YK. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer:a randomised phaseⅢ noninferiority trial. Ann Oncol,2009,20(4):666-673 CSCD被引 35 次    
7.  Cunningham D. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med,2008,358(1):36-46 CSCD被引 91 次    
8.  Okines AF. Meta-analysis of the REAL-2 and ML17032 trials:evaluating capecitabinebased combination chemotherapy and infused 5-fluorouracilbased combination chemotherapy for the treatment of advanced oesophago-gastric cancer l. Ann Oncol,2009,20(9):1529-1534 CSCD被引 14 次    
9.  Park YH. Capecitabine in combination with oxaliplatin(XELOX)as a first-line therapy for advanced gastric cancer. Cancer Chemother Phar Macol,2008,61(4):623-629 CSCD被引 13 次    
10.  Liu C. Multicencer phaseⅡstudy of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer. Anticancer Drugs,2008,19(8):825-831 CSCD被引 5 次    
11.  Quek R. Capecitabine and oxaliplatin(XELOX)is safe and effective in patients with advanced gastric cancer. Acta Onco,2007,46(7):1032-1034 CSCD被引 4 次    
12.  陈学明. 奥沙利铂联合希罗达治疗晚期胃癌近期疗效观察. 肿瘤防治杂志,2005,12(4):303-304 CSCD被引 4 次    
引证文献 1 篇

1 迟惠昌 益气活血中药配合化学药物治疗晚期胃癌疗效观察 中华中医药杂志,2011,26(8):1888-1890
CSCD被引 2 次

显示所有1篇文献

论文科学数据集
PlumX Metrics
相关文献

 作者相关
 关键词相关
 参考文献相关

版权所有 ©2008 中国科学院文献情报中心 制作维护：中国科学院文献情报中心
地址：北京中关村北四环西路33号 邮政编码：100190 联系电话：(010)82627496 E-mail:cscd@mail.las.ac.cn 京ICP备05002861号-4 | 京公网安备11010802043238号